Feline Infectious Peritonitis: Welfare and New Treatment Options
FIP (feline infectious peritonitis) was once universally fatal but antiviral treatments have transformed outcomes. This page reviews FIP pathogenesis, welfare impact, and the welfare implications of new curative treatments.
What Is FIP?
Feline infectious peritonitis results from a mutation of feline enteric coronavirus (FECV) to a virulent biotype (FIPV) causing systemic inflammatory disease. Most cats are exposed to FECV without ill effects; FIP develops in approximately 5-10% of FECV-positive cats, typically young cats under 2 years or immunocompromised individuals. The mutated virus infects macrophages, causing systemic vasculitis and granulomatous inflammation. Two clinical forms exist: wet (effusive, with body cavity fluid accumulation) and dry (non-effusive, with granulomatous lesions in organs).
Welfare Impact of FIP
Untreated FIP causes progressive, severe welfare compromise over weeks to months. Wet FIP causes breathlessness (pleural effusion), abdominal distension, and discomfort from fluid accumulation. Dry FIP causes neurological signs (seizures, ataxia, behavioural change), ocular disease (uveitis causing pain and blindness), and systemic illness. Weight loss, lethargy, and anorexia occur in both forms. The combination of multiple organ involvement, progressive deterioration, and historically 100% fatality made FIP one of the most welfare-significant feline diagnoses.
Antiviral Revolution: GS-441524 and Remdesivir
Since 2019, antiviral treatment with nucleoside analogues—primarily GS-441524 (the active form of remdesivir)—has transformed FIP outcomes. Clinical remission is achieved in approximately 85-90% of cats receiving appropriate dosing for 12 weeks. Cats that achieve remission and survive the 12-week observation period after treatment cessation have excellent long-term prognoses. This welfare transformation—from inevitable death to likely cure—is one of the most dramatic developments in feline medicine.
Treatment Access and Welfare Equity
GS-441524 was not initially licensed for veterinary use; cats were treated with unlicensed compounds, creating regulatory and safety challenges. Licensed products (Bova GS, Euraferon) are now available in some markets. Treatment costs (several hundred to over a thousand pounds per course) create welfare equity issues—not all owners can access life-saving treatment. Welfare organisations and cost-sharing programmes are developing to address this; veterinary practices should be aware of financial assistance options for clients facing this diagnosis.
Monitoring During Treatment
Treatment monitoring is essential for welfare optimisation: regular clinical assessment, body weight monitoring, laboratory parameters (protein electrophoresis, albumin:globulin ratio, PCV), and effusion volume assessment guide dose and duration decisions. Cats that initially respond then relapse may require dose escalation. Neurological FIP requires higher doses and careful monitoring for neurological improvement. Welfare monitoring must assess quality of life alongside clinical parameters—a cat that is not improving clinically and showing welfare decline warrants honest reassessment.
Post-Treatment Welfare
Cats achieving sustained remission after FIP treatment return to normal or near-normal quality of life in the majority of cases. Residual neurological deficits (from dry FIP with CNS involvement) may persist but are often mild and manageable. Ocular changes from uveitis may leave permanent (though manageable) eye disease. Follow-up veterinary care assessing for relapse (less than 10% with completed treatment courses) and managing residual complications is the welfare standard for treated cats.
Owner Support and Decision-Making
FIP diagnosis is a crisis for owners. Supporting owners through: accurate prognostic information about treatment outcomes; treatment cost implications; monitoring requirements; and realistic expectations for outcome supports informed decision-making. For owners who cannot access or afford treatment, honest discussion of palliative care options and quality-of-life timelines allows dignified end-of-life care rather than prolonged suffering. Welfare is served by honest, compassionate communication as much as by medical intervention.
Summary
FIP illustrates the transformative welfare impact of effective antiviral treatment. Welfare management has shifted from palliative care and euthanasia to active curative intent for most cats. Welfare priorities now include treatment access equity, monitoring compliance, management of treatment-related complications, and long-term follow-up. The FIP treatment revolution represents one of the most significant welfare advances in feline medicine.